In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

STRATA Skin Sciences, Inc.

https://www.strataskinsciences.com/

Latest From STRATA Skin Sciences, Inc.

Deal Watch: Merck Gets Rights To Yumanity’s Preclinical ALS, FTLD Candidates

Merck pays undisclosed upfront fees and promises up to $500m for milestones under licensing and collaboration agreement. Meanwhile, Tetraphase and Xerava are being acquired by La Jolla, after previous bids by Melinta and AcelRx.

Deals Business Strategies

Deal Watch: GSK Invests In Early-Stage Synthetic Lethality Programs At Ideaya

Pharma pays $100m up front and makes $20m equity investment for rights to three preclinical cancer programs. Plus more than 20 deal summaries, including COVID-19-related transactions.

Oxford’s COVID-19 Vaccine Makers To Parallel Clinical Studies

An industry consortium will drive forward new manufacturing processes in parallel with the Oxford group’s COVID-19 vaccine clinical studies; these studies could produce Phase III efficacy results by this autumn.

Coronavirus COVID-19 Manufacturing

FDA Commissioner Candidate Gulfo Hates Breakthrough, Wants To Reevaluate User Fees

In an interview, Joseph Gulfo, former medtech industry CEO and vocal FDA critic, outlines his worldview and interest in pushing aggressively against increasing the FDA ‘body of law.’

Drug Approval Standards FDA
See All

Company Information

  • Industry
  • Medical Devices
    • Laser
  • Other Names / Subsidiaries
    • Electro-Optical Sciences, Inc.
    • MELA Sciences
UsernamePublicRestriction

Register